Imara re­duced to six em­ploy­ees as the biotech, once again pre­clin­i­cal, ex­plores its op­tions

Imara will em­ploy just six peo­ple by the end of this quar­ter as 83% of the staff has been shown the ex­it fol­low­ing the biotech’s Phase IIb flops ear­li­er this month.

The com­pa­ny will like­ly have to find a buy­er or shut down. Imara’s main goal and like­ly on­ly pri­or­i­ty at this point — af­ter end­ing work on its sick­le cell dis­ease and be­ta-tha­lassemia drug — is un­der­go­ing a “com­pre­hen­sive as­sess­ment of its strate­gic op­tions to max­i­mize share­hold­er val­ue.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER